Zejula 100 mg film-coated tablets, Zejula 100 mg film-coated tablets clinical trials

A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of the oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP inhibitor (PARPi) niraparib in adult participants with solid tumors.

This study looks at a new drug, GSK4524101, combined with an existing cancer drug, niraparib (Zejula), for adults with solid tumours. It aims to find a safe dose and see how well the combination shrinks tumours and manages cancer.